Package | us.nlm.vsac |
Type | ValueSet |
Id | 2.16.840.1.113762.1.4.1078.926 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1078.926/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.926 |
Version | 20240709 |
Status | active |
Date | 2024-07-09T01:07:16-04:00 |
Name | CanagliflozinMeds |
Title | Canagliflozin meds |
Realm | us |
Authority | hl7 |
Purpose | (Clinical Focus: Medications containing canagliflozin),(Data Element Scope: RxCUIs at product level (SCD, GPCK, SBD, BPCK)),(Inclusion Criteria: Valid, prescribable RxCUIs (including retried RxCUIs) with canagliflozin as ingredient),(Exclusion Criteria: Invalidated RxCUIs) |
ValueSet | |
2.16.840.1.113762.1.4.1078.933 | T2DM meds benefitting ASCVD |
2.16.840.1.113762.1.4.1078.934 | T2DM meds benefitting CKD stages 2, 3, and 4 with eGFR >= 20 mL/min |
2.16.840.1.113762.1.4.1078.936 | T2DM meds benefitting HF with eGFR >= 20 mL/min |
CodeSystem | |
rxnorm | RxNorm |
rxnorm | RxNorm |
No narrative content found in resource